Malignancy is among the primary causes of mortality in renal transplant recipients. The risk of new malignancies in renal transplant recipients is 2–3 times higher than in the general population. 1 If a possible recipient has a cancer history, a waiting period before renal transplantation is often required after cancer treatment. Immunosuppression after renal transplantation might not affect the prognosis of low‐risk renal cell carcinomas. 2 Posttransplant malignancies, which can occur de novo or as cancer recurrences, result from chronic exposure to immunosuppressive drugs and are often more aggressive than those that develop in the nontransplant setting. Malignancy after renal transplantation requires cautious and long‐term follow‐up.
Inoue et al. reported a case of renal cell carcinoma recurrence in a patient who received simultaneous treatment with radical nephrectomy for a left renal tumor and cadaver renal transplantation. 3 The tumor was a clear cell carcinoma (G2, pT1b). Twelve years after renal transplantation, an anterior mediastinal mass and lung and bilateral adrenal metastases were observed. Noteworthy points of this case are the association between immunosuppressive drugs and recurrence and the effect of simultaneous treatment with radical nephrectomy and renal transplantation on tumor control in patients with renal cancer.
Mammalian target of rapamycin (mTOR) inhibitors have immunosuppressive and antitumor effects. Treatment conversion to mTOR inhibitors is correlated with a low incidence of malignancies and is safe for renal function and graft survival in patients with a cancer history. 4 The use of immune checkpoint inhibitors is another treatment option for renal cancer. However, it might be associated with a high risk of acute rejection. 5 Renal transplantation might not be correlated with a high risk of recurrence compared with dialysis in patients with low‐risk renal cancer. 2 Nevertheless, recurrence of malignancy after renal transplantation requires cautious and long‐term follow‐up. Expectantly, considering the various risks in renal transplant recipients, optimal treatment regimens with immunosuppressive drugs and standard doses will be determined in the future.
Conflict of interest
The author declares no conflict of interest.
References
- 1. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am. J. Transplant. 2007; 7: 2140–51. [DOI] [PubMed] [Google Scholar]
- 2. Boissier R, Hevia V, Bruins HM et al. The risk of tumour recurrence in patients undergoing renal transplantation for end‐stage renal disease after previous treatment for a urological cancer: a systematic review. Eur. Urol. 2018; 73: 94–108. [DOI] [PubMed] [Google Scholar]
- 3. Inoue S, Shioya A, Kunii K et al. A case of recurrence of renal cell carcinoma after simultaneous radical nephrectomy and cadaver renal transplant. IJU Case Rep. 2022; 5: 397–400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Naik MG, Arns W, Budde K et al. Sirolimus in renal transplant recipients with malignancies in Germany. Clin. Kidney J. 2021; 14: 2047–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Murakami N, Mulvaney P, Danesh M et al. A multi‐center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021; 100: 196–205. [DOI] [PMC free article] [PubMed] [Google Scholar]